Michal Mrug

Michal Mrug
Professor

Associate Scientist (C), Heflin Genetics Center , School of Medicine
Senior Scientist (C), Center for Clinical and Translational Science (CCTS) , General Clinical Research Center
Senior Scientist (C), Nephrology Research & Training Center , General Clinical Research Center
Professor (P), Medicine - Nephrology , Department of Medicine

Overview

Dr. Mrug is a Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) where he trains the next generation of physicians and scientists. Dr. Mrug is recognized as one of “Top Doctors” by Castle Connolly Medical Ltd. He co-founded and directs the UAB Polycystic Kidney Disease (PKD) Clinic and oversees clinical PKD research activities at UAB (since 2009). This includes the CRISP study, an NIH-funded collaborative effort between Emory University, University of Kansas, Mayo Clinic, UAB and University of Pittsburgh that has led to many seminal discoveries. He also coordinated the REPRISE clinical trial for UAB; outcomes of this study played a crucial role in the recent FDA approval of tolvaptan as the first treatment for autosomal dominant PKD (ADPKD). Dr. Mrug’s clinical research interests are centered on the development of statistical models for prediction of the decline in the kidney function in patients with ADPKD over time and better identification of those patients that may benefit most from therapeutic interventions. Dr. Mrug’s basic research (funded since 2005) is focused on the identification of molecular pathways that modulate progression of renal cystic diseases, especially those related to inflammation. He also directs the Therapeutics Development and Screening Core, one of four cores within the UAB Hepatorenal Fibrocystic Disease Core Center (HRFD CC). The UAB HRFD CC is one of four NIH-funded P30 centers focused on PKD, with the other three PKD Core Centers being located at University of Kansas, Mayo Clinic and University of Maryland. The mission of these centers is the development of innovative technologies to advance PKD research and providing access to these resources to other scientists to help them promote PKD research in institutions where such resources are not available. The activities of the UAB HRFD CC are centered on Autosomal Recessive PKD (ARPKD) and other recessive fibrocystic disorders affecting the kidney and liver. Dr. Mrug also serves as the Scientific Advisory Committee Chair for the PKD Foundation’s Board of Trustees.

Selected Publications

Academic Article

Year	Title	Altmetric
2022	CD206+ resident macrophages are a candidate biomarker for renal cystic disease in preclinical models and patients with ADPKD.. Disease Models and Mechanisms. 2022
2022	Red blood cell exosome hemoglobin content increases after cardiopulmonary bypass and mediates acute kidney injury in an animal model. Journal of Thoracic and Cardiovascular Surgery. 164:e289-e308. 2022
2022	The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD. Kidney Medicine. 4. 2022
2022	Design and Basic Characteristics of a National Patient-Powered Registry in ADPKD. 2022
2022	A Comprehensive Immune Cell Atlas of Cystic Kidney Disease Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice. Journal of the American Society of Nephrology. 33:747-768. 2022
2022	Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology. 17:374-384. 2022
2022	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics. 109:136-156. 2022
2021	Genetic Testing for Chronic Kidney Diseases: Clinical Utility and Barriers Perceived by Nephrologists. Kidney Medicine. 3:1050-1056. 2021
2021	Early infiltrating macrophage subtype correlates with late-stage phenotypic outcome in a mouse model of hepatorenal fibrocystic disease. Laboratory Investigation. 101:1382-1393. 2021
2021	Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports. 6:953-961. 2021
2020	Autosomal Dominant Polycystic Kidney Disease does not significantly alter major COVID-19 outcomes among veterans. 2020
2020	Role of chemokines, innate and adaptive immunity. Cellular Signalling. 73. 2020
2020	The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 5. 2020
2019	Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease. Cell Metabolism. 30:1007-1023.e5. 2019
2019	Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. Journal of Clinical Investigation. 129:4506-4522. 2019
2019	Growth pattern of kidney cyst number and volume in autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology. 14:823-833. 2019
2019	Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney International. 95:1253-1261. 2019
2019	Single-cell RNA sequencing identifies candidate renal resident macrophage gene expression signatures across species. Journal of the American Society of Nephrology. 30:767-781. 2019
2019	Heterozygous Pkhd1^C642* mice develop cystic liver disease and proximal tubule ectasia that mimics radiographic signs of medullary sponge kidney 2019
2019	Truncating PKHD1 and PKD2 mutations alter energy metabolism 2019
2019	Resident macrophages reprogram toward a developmental state after acute kidney injury. JCI Insight. 4. 2019
2019	Mks6 mutations reveal tissue-and cell type-specific roles for the cilia transition zone 2019
2019	Sodium and potassium excretion predict increased depression in urban adolescents. Physiological Reports. 7. 2019
2019	Tissue-resident macrophages promote renal cystic disease. Journal of the American Society of Nephrology. 30:1841-1856. 2019
2019	Urinary T cells correlate with rate of renal function loss in autosomal dominant polycystic kidney disease. Physiological Reports. 7. 2019
2018	Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: A retrospective analysis using the CRISP cohort. BMC Nephrology. 19. 2018
2018	A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. Journal of the American Society of Nephrology. 29:2458-2470. 2018
2018	Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8 2018
2018	Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney International. 93:691-699. 2018
2017	Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney International. 92:1206-1216. 2017
2017	Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases. 69:482-484. 2017
2017	Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy.. SAGE Open Medical Case Reports. 5:2050313X17705050. 2017
2017	Uric Acid Excretion Predicts Increased Blood Pressure Among American Adolescents of African Descent. American Journal of the Medical Sciences. 353:336-341. 2017
2016	International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection 2016
2016	Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease. Physics in Medicine and Biology. 61:7864-7880. 2016
2016	Uric acid excretion predicts increased aggression in urban adolescents. Physiology and Behavior. 163:144-148. 2016
2016	Automated segmentation of kidneys from mr images in patients with autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology. 11:576-584. 2016
2016	Predicted mutation strength of nontruncating PKD1 mutations AIDS genotype-phenotype correlations in autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology. 27:2872-2884. 2016
2015	Genetic and informatic analyses implicate Kif12 as a candidate gene within the Mpkd2 locus that modulates renal cystic disease severity in the Cys1^cpk mouse. PLoS One. 10. 2015
2015	A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney International. 88:146-151. 2015
2015	Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 88:17-27. 2015
2015	Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. Journal of the American Society of Nephrology. 26:160-172. 2015
2014	Complement C3 activation in cyst fluid and urine from autosomal dominant polycystic kidney disease patients. Journal of Internal Medicine. 276:539-540. 2014
2014	Novel methodology to evaluate renal cysts in polycystic kidney disease. American Journal of Nephrology. 39:210-217. 2014
2013	Innovations in studying in vivo cell behavior and pharmacology in complex tissues - Microvascular endothelial cells in the spotlight. Cell and Tissue Research. 354:647-669. 2013
2013	Beware the low HDAC11: Males at risk for ischemic kidney injury 2013
2013	Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. American Journal of Nephrology. 38:333-341. 2013
2013	Segmentation of individual renal cysts from mr images in patients with autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology. 8:1089-1097. 2013
2013	Proximal tubule proliferation is insufficient to induce rapid cyst formation after cilia disruption. Journal of the American Society of Nephrology. 24:456-464. 2013
2013	Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study. PLoS One. 8. 2013
2013	Renal macrophages in autosomal recessive polycystic kidney disease. Nephrology. 18:746. 2013
2012	Impact of ultrasound-guided kidney biopsy simulation on trainee confidence and biopsy outcomes. American Journal of Nephrology. 36:570-574. 2012
2012	Microarray analysis of normal and abnormal chick ventricular myocardial development. Physiological Research. 61. 2012
2012	Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement. Journal of the American Society of Nephrology. 23:1161-1171. 2012
2011	Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology. 6:640-647. 2011
2010	Comprehensive human urine standards for comparability and standardization in clinical proteome analysis 2010
2010	Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney International. 78:550-560. 2010
2010	Simulation of real-time ultrasound-guided renal biopsy. Kidney International. 78:705-707. 2010
2009	Validation of endogenous internal real-time PCR controls in renal tissues. American Journal of Nephrology. 30:413-417. 2009
2009	C3 polymorphisms and outcomes of renal allografts. New England Journal of Medicine. 360:2477-2479. 2009
2008	Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney International. 73:63-76. 2008
2008	Response to 'Overexpression of complement-component genes in Han:SPRD rats a model of polycystic kidney disease'. Kidney International. 73:1325. 2008
2006	Blood-borne stem cells differentiate into vascular and cardiac lineages during normal development. Stem Cells and Development. 15:17-28. 2006
2005	Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse. Journal of the American Society of Nephrology. 16:905-916. 2005
2004	Angiotensin II Receptor Type 1 Expression in Erythroid Progenitors: Implications for the Pathogenesis of Postrenal Transplant Erythrocytosis. Seminars in Nephrology. 24:120-130. 2004
2002	Refinement of the autosomal recessive polycystic kidney disease (PKHD1) interval and exclusion of an EF hand-containing gene as a PKHD1 candidate gene. American Journal of Medical Genetics Part A. 110:346-352. 2002
2002	Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease.. Journal of Clinical Investigation. 109:533-540. 2002
2002	Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. Journal of Clinical Investigation. 109:533-540. 2002
2002	Hemothorax and retroperitoneal hematoma after anticoagulation with enoxaparin. Southern Medical Journal. 95:936-938. 2002
2002	Not one but two inflammatory bowel disease susceptibility loci map to chromosome 16. American Journal of Gastroenterology. 97:2464-2465. 2002
2002	PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. American Journal of Human Genetics. 70:1305-1317. 2002
2001	An integrated genetic and physical map of the 650-kb region containing the congenital polycystic kidney (cpk) locus on mouse chromosome 12. Cytogenetic and Genome Research. 94:55-61. 2001
2001	Non-anemic homozygous β thalassemia in an african-american family: Association of high fetal hemoglobin levels with β thalassemia alleles. American Journal of Hematology. 68:43-50. 2001
2000	Genomic structure of the gene for the human p1 protein (MCM3) and its exclusion as a candidate for autosomal recessive polycystic kidney disease. European Journal of Human Genetics. 8:163-166. 2000
2000	Mapping of mouse α1(XIII) collagen to chromosome 10 and its exclusion as a kd candidate gene. Biochemical Genetics. 38:337-340. 2000
1999	Genomic organization of the KIAA0057 gene that encodes a TRAM-like protein and its exclusion as a polycystic kidney and hepatic disease 1 (PKHD1) candidate gene. Mammalian Genome. 10:1175-1178. 1999
1997	Angiotensin II stimulates proliferation of normal early erythroid progenitors. Journal of Clinical Investigation. 100:2310-2314. 1997
1997	'Complicated' autosomal dominant familial spastic paraplegia is genetically distinct from 'pure' forms. JAMA Neurology. 54:379-384. 1997
1997	The gene for autosomal dominant craniometaphyseal dysplasia maps to chromosome 5p and is distinct from the growth hormone-receptor gene. American Journal of Human Genetics. 61:918-923. 1997
1996	Identification of highly polymorphic microsatellites in the rhesus macaque Macaca mulatta by cross-species amplification. Molecular Ecology. 5:157-159. 1996
1993	Polymorphisms in the pseudoautosomal regions of X and Y in DNA diagnosis. Vnitrni lekarstvi. 39:959-963. 1993